Prostate Cancer Clinical Trials in Phoenix, Arizona

8 studies are recruiting for prostate cancer in Phoenix, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

   The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adv…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Phoenix, Arizona

   Locations

   346 in total

   Run by

   AstraZeneca

   See if you can join NCT06952803 on ClinicalTrials.gov

2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

   Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic in Arizona - Phoenix ( Site 0044), Phoenix, Arizona

   Locations

   298 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06925737 on ClinicalTrials.gov

3. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

   The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic- Phoenix, Phoenix, Arizona

   Locations

   34 in total

   Run by

   Clarity Pharmaceuticals Ltd

   See if you can join NCT06056830 on ClinicalTrials.gov

4. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

5. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

   This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Phoenix, Arizona

   Locations

   337 in total

   Run by

   Pfizer

   See if you can join NCT07028853 on ClinicalTrials.gov

6. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   36 in total

   Run by

   Janux Therapeutics

   See if you can join NCT05519449 on ClinicalTrials.gov

7. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

   This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   14 in total

   Run by

   858 Therapeutics, Inc.

   See if you can join NCT06395519 on ClinicalTrials.gov

8. Understanding of Genetics by Men at Risk for Prostate Cancer

   With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understanding of prognostic genetic technology in African American and rural White men at risk for localized …

   Stage

   Not phased

   Ages

   40 to 95

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   3 in total

   Run by

   Mayo Clinic

   See if you can join NCT04550845 on ClinicalTrials.gov